within Pharmacolibrary.Drugs.ATC.L;

model L01EX27
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.73,
    Cl             = 0.0009383333333333332,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.094,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010333333333333333,
    Tlag           = 15.0,            
    Vdp             = 0.074,
    k12             = 90,
    k21             = 90
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EX27</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Capivasertib is an oral, selective pan-AKT kinase inhibitor developed for the treatment of various cancers, including breast cancer. It is currently approved in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in adults who have received prior endocrine therapy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients after oral administration; values based on phase I/II clinical trials.</p><h4>References</h4><ol><li><p>Fernandez-Teruel, C, et al., &amp; Zhou, D (2024). Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours. <i>Clinical pharmacokinetics</i> 63(8) 1191–1204. DOI:<a href=&quot;https://doi.org/10.1007/s40262-024-01407-x&quot;>10.1007/s40262-024-01407-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39127854/&quot;>https://pubmed.ncbi.nlm.nih.gov/39127854</a></p></li><li><p>Miller, C, et al., &amp; Cullberg, M (2024). Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 94(2) 223–235. DOI:<a href=&quot;https://doi.org/10.1007/s00280-024-04667-3&quot;>10.1007/s00280-024-04667-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38643311/&quot;>https://pubmed.ncbi.nlm.nih.gov/38643311</a></p></li><li><p>Banerji, U, et al., &amp; Schellens, JHM (2018). A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in . <i>Clinical cancer research : an official journal of the American Association for Cancer Research</i> 24(9) 2050–2059. DOI:<a href=&quot;https://doi.org/10.1158/1078-0432.CCR-17-2260&quot;>10.1158/1078-0432.CCR-17-2260</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29066505/&quot;>https://pubmed.ncbi.nlm.nih.gov/29066505</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EX27;
